FindTrial
Sign In

D-1553

DRUG6 trials

Sponsors

InventisBio Co., Ltd, Suzhou Genhouse Bio Co., Ltd.

Conditions

CRCHealthy MaleLocally Advanced or Metastatic Solid Tumors Harboring KRAS G12C MutationNSCLCSolid TumorSolid Tumor, Adult

Phase 1

Study to Evaluate D-1553 in Subjects With Solid Tumors
Active, not recruitingNCT04585035
InventisBio Co., LtdCRC, NSCLC, Solid Tumor, Adult
Start: 2020-10-02End: 2025-12-31Updated: 2025-03-18
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Active, not recruitingNCT05379946
InventisBio Co., LtdSolid Tumor
Start: 2022-10-12End: 2025-12-31Target: 92Updated: 2025-04-08
Study to Evaluate D-1553 in Subjects With Lung Cancer
CompletedNCT05383898
InventisBio Co., LtdNSCLC
Start: 2021-03-16End: 2024-05-17Updated: 2024-10-15
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
TerminatedNCT05492045
InventisBio Co., LtdNSCLC
Start: 2022-09-13End: 2024-06-14Updated: 2024-10-15
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
CompletedNCT06105255
InventisBio Co., LtdHealthy Male
Start: 2023-05-24End: 2024-02-02Updated: 2024-10-15
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
Not yet recruitingNCT06435455
Suzhou Genhouse Bio Co., Ltd.Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Start: 2024-07-01End: 2027-12-31Target: 126Updated: 2024-07-08

Related Papers

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.
2025-12-04
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.
2025-11-29
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
2025-06-178 citations
Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).
Journal of Clinical Oncology2025-05-28
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.
2024-06-1025 citations
Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.
Journal of Clinical Oncology2024-06-017 citations
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
Journal of Clinical Oncology2023-06-0110 citations
Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation
Cancer Research2022-06-153 citations
Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation
Cancer Research2022-06-151 citations
Abstract 932: Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Cancer Research2021-07-0126 citations
Abstract 1056: Potent <i>in vivo</i> anti-tumor activity of D-1553 as a single agent and in combination with targeted therapeutics in a broad spectrum of patient-derived xenograft tumor models with KRas G12C mutation
Cancer Research2021-07-015 citations